Lotery, Andrew J. and Burdon, Michael A. (2018) Bevacizumab: a new way of doing business. Part 2. Eye, 33 (4), 519-520. (doi:10.1038/s41433-018-0281-2).
Record type:
Editorial
Full text not available from this repository.
More information
Accepted/In Press date: 7 November 2018
e-pub ahead of print date: 27 November 2018
Identifiers
Local EPrints ID: 430663
URI: http://eprints.soton.ac.uk/id/eprint/430663
ISSN: 0950-222X
PURE UUID: 5c3669e1-30c8-45e8-b759-2dba1c09d36f
Catalogue record
Date deposited: 08 May 2019 16:30
Last modified: 07 Oct 2020 01:48
Export record
Altmetrics
Contributors
Author:
Michael A. Burdon
University divisions
- Faculties (pre 2018 reorg) > Faculty of Medicine (pre 2018 reorg) > Clinical & Experimental Sciences (pre 2018 reorg)
Current Faculties > Faculty of Medicine > Clinical and Experimental Sciences > Clinical & Experimental Sciences (pre 2018 reorg)
Clinical and Experimental Sciences > Clinical & Experimental Sciences (pre 2018 reorg) - Current Faculties > Faculty of Medicine > Clinical and Experimental Sciences
Clinical and Experimental Sciences
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.